Literature DB >> 1980841

Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP.

N A Seniuk1, W G Tatton, C E Greenwood.   

Abstract

In order to determine whether 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces neuronal death or the loss of tyrosine hydroxylase (TH) immunoreactivity, 4 catecholaminergic nuclei in the mouse: substantia nigra compacta (SNc), locus coeruleus (LC), ventral tegmental area (VTA) and the A13 nucleus in the hypothalamus were quantitatively examined. Serial sections were taken through the rostrocaudal extent of each nucleus: alternate sections were incubated with TH antiserum and reacted with an immunoperoxidase technique while the alternate set was Nissl stained. Counts and 3 dimensional reconstructions of TH reactive somata were made for each nucleus for saline-treated controls and mice treated with different doses of MPTP (37.5, 75, 150 and 300 mg/kg). TH-positive neurons were counted along with their counterparts on the Nissl-stained alternative sections to both identify the catecholaminergic neurons and to measure their destruction. Concentrations of striatal dopamine and cortical norepinephrine were measured for all dosages of MPTP in order to determine the relationship between dosage, target tissue neurotransmitter concentration and neuronal destruction. By 20 days after MPTP injection there was a dose-dependent random loss of TH-immunoreactive neurons that was almost identical in all 4 nuclei examined. Analysis of the Nissl versus TH cell counts revealed that MPTP resulted in neuronal destruction in the SNc and the LC rather than just a loss of TH immunoreactivity. There was no difference in sensitivity to MPTP between the SNc and the LC. Decreases in cortical norepinephrine concentrations were about one third of the decreases of LC neuronal counts for all MPTP doses; while decreases in striatal dopamine and SNc cell loss was similar to the LC for the two lower doses of MPTP but for the higher doses, the relationship approached or exceeded a one to one ratio. Hence estimates of neuronal death based upon target tissue transmitter concentrations could not be made using the same relationship for SNc and the LC catecholaminergic neurons and use of the same relationship for higher MPTP dosages results in an underestimate of LC neuronal destruction relative to that in the SNc.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1980841     DOI: 10.1016/0006-8993(90)91055-l

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  27 in total

Review 1.  Glial cell response: A pathogenic factor in Parkinson's disease.

Authors:  Du Chu Wu; Kim Tieu; Oren Cohen; Dong-Kug Choi; Miquel Vila; Vernice Jackson-Lewis; Peter Teismann; Serge Przedborski
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Chronic deprivation of TrkB signaling leads to selective late-onset nigrostriatal dopaminergic degeneration.

Authors:  Maryna Baydyuk; Madeline T Nguyen; Baoji Xu
Journal:  Exp Neurol       Date:  2010-12-28       Impact factor: 5.330

Review 3.  The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders.

Authors:  Jesse Costales; Alexander Kolevzon
Journal:  Neurosci Biobehav Rev       Date:  2016-01-15       Impact factor: 8.989

4.  14-3-3 inhibition promotes dopaminergic neuron loss and 14-3-3θ overexpression promotes recovery in the MPTP mouse model of Parkinson's disease.

Authors:  H Ding; R Underwood; N Lavalley; T A Yacoubian
Journal:  Neuroscience       Date:  2015-08-24       Impact factor: 3.590

5.  Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production.

Authors:  Zhi-Guo Zhang; Lin Wu; Ju-Lei Wang; Jian-Dong Yang; Jing Zhang; Jian Zhang; Li-Hong Li; Yi Xia; Li-Bo Yao; Huai-Zhou Qin; Guo-Dong Gao
Journal:  Mol Cell Biochem       Date:  2012-01-26       Impact factor: 3.396

Review 6.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

Review 7.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

9.  Neuroprotective effects of alpha-dihydroergocryptine against damages in the substantia nigra caused by severe treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  G Bernocchi; G Gerzeli; E Scherini; C Vignola
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

10.  Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.

Authors:  Gulnara R Khakimova; Elena A Kozina; Valerian G Kucheryanu; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2016-05-19       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.